| Biomarker ID | 648 |
| PMID | 21520154 |
| Year | 2011 |
| Biomarker | PSMA + PSGR + PCA3 + PSA |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Urine |
| Subjects | Humans |
| Regulation | Differentially Expressed |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(FOLH1) :-One-carbon metabolism,TNF-alpha effects on cytokine activity, cell motility, and apoptosis, T cell receptor regulation of apoptosis Pathways Include(O51E2) :- Olfactory transduction,Signaling by GPCR Pathways Include(KLK3):- ID regulation of gene expression,Prostate cancer, Androgen receptor proteolysis and transcription regulation, Androgen receptor signaling, proteolysis, and transcription regulation, Insulin-like growth factor (IGF) activity regulation by insulin-like growth factor binding proteins (IGFBPs) |
| Experiment | (Prostate Cancer Vs Benign) with PSA in range 4-10ng/ml |
| Type of Biomarker | Diagnostic |
| Cohort | Samples for Benign (n=54) and PCA (n=28) were taken into account for this study such that they had PSA in the range 4-10ng/ml. |
| Senstivity | NA |
| Specificity | NA |
| AUC | 0.77 |
| Accuracy | NA |
| Level Of Significance | NA |
| Method Used | qPCR |
| Clinical | No |
| Remarks | Briefly, 50% of the sample was used as a training set to compute a ROC curve. |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | FOLH1, OR51E2, PCA3, KLK3 |